A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).

The main purpose for this study is to determine whether dimebon exhibits abuse potential.

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years.
• Recreational polydrug user with a history of CNS depressant use.

Exclusion Criteria:

• History of clinically significant neurologic condition(s), such as seizures, convulsions, epilepsy, or significant head injury, as judged by the investigator or designee.
• A known history of hypersensitivity or previous intolerance to dimebon or other antihistamines.
• Self-reported history of drug or alcohol dependence (except nicotine or caffeine) in the 2 years prior to screening, or drug or alcohol dependence as defined by the (DSM-IV-TR) in 12 months prior to screening, including subjects who have ever been in a substance rehabilitation program (other than treatment for smoking cessation).
• History of clinically significant psychiatric disorder(s), as judged by the investigator or qualified designee.